LONDON, Nov. 03, 2025 (GLOBE NEWSWIRE) -- ECARX Holdings Inc. (Nasdaq: ECX) (“ECARX” or the “Company”), a global mobility tech provider, today announced unaudited financial results for the quarter ended September 30, 2025. Ziyu Shen, ECARX Chairman and CEO, commented, “The strong momentum from the first half of the year carried through into Q3, delivering several significant milestones that are reinforcing the sustainable foundation we are building for future growth. Most notably, we achieved EBITDA breakev ...

ACQUIRES FOUR COMMUNITIES IN INDIANA AND OHIO FOR TOTAL CONSIDERATION OF US$79 MILLIONNot for distribution to U.S. newswire services or dissemination in the United States. TORONTO, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Flagship Communities Real Estate Investment Trust (TSX:MHC.U) (TSX:MHC.UN) (“Flagship” or the “REIT”) today announced two strategic acquisitions for total consideration of US$79 million, expanding its presence in both Indiana and Ohio (the “Acquisitions”). The Acquisitions are expected to be imme ...

NEW YORK, Nov. 03, 2025 (GLOBE NEWSWIRE) -- OTC Markets Group Inc. (OTCQX: OTCM), operator of regulated markets for trading 12,000 U.S. and international securities, today announced Meren Energy Inc. (Nasdaq Stockholm: MER; TSX: MER; OTCQX: MRNFF), a full-cycle Independent upstream oil and gas company, has qualified to trade on the OTCQX® Best Market. Meren Energy Inc. upgraded to OTCQX from the Pink Limited™ Market. Meren Energy Inc. begins trading today on OTCQX under the symbol “MRNFF.” U.S. investors ca ...

First clinical data disclosure for CB-011 highlights its potential as a best-in-class allogeneic CAR-T cell therapy for relapsed or refractory multiple myeloma450 million cell dose is the recommended dose for expansion (RDE); dose expansion to initiate by year end and data expected in 202692% ORR, 75% ≥CR rate, 91% MRD negativity in the 12-patient, BCMA-naïve cohort treated at the RDE with the selected lymphodepletion regimenConference call and webcast scheduled for today at 8:00 am ET BERKELEY, Calif., Nov ...

Xanadu Produced the First Networked, Modular and Scalable Quantum Computer with their Aurora System in Early 20251First Pure Play Quantum Computing Company to Achieve Quantum Supremacy with their Borealis System in 2022 Xanadu’s PennyLane Software Offering is the #1 Quantum Programming Software with 47% Usage Among Quantum Programmers2Pro Forma Enterprise Value of the Combined Company is Expected to be Approximately US$3.1 Billion and Pro Forma Market Capitalization is Expected to be Approximately US$3.6 Bi ...

26% Objective Response Rate Median Duration of Response Not Reached after 25 Months Follow Up Lifileucel Launch in Previously Treated Advanced NSCLC Expected in Second Half of 2027 SAN CARLOS, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced interim data from its registrational Ph ...

First successful end-to-end on-wing calls already completed. Gogo begins flight testing next-generation 5G ATG connectivity on Pilatus PC-24 jet MB-13 antennas equipped to belly of the fuselage connect with the Gogo 5G tower network Broomfield, CO., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Gogo (NASDAQ: GOGO) has begun flight testing its next-generation 5G air-to-ground connectivity network for North American customers. Optimizing a Pilatus PC-24 trials platform, the test team is flying on alternate days during ...

On 5 May 2025, Schouw & Co. initiated a share buy-back programme as outlined in Company Announcement no. 20 of 2 May 2025. Under the programme, Schouw & Co. will acquire shares for up to DKK 120 million during the period 5 May to 31 December 2025. The buy-back will be structured in accordance with Regulation (EU) No. 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse (MAR) and the Commission’s delegated regulation (EU) 2016/1052 of 8 March 2016 (“Safe Harbour” rules). Tr ...

Total 3Q 2025 net product revenue of $171.0 million, representing 63% year-over-year growth AUVELITY® 3Q 2025 net product sales of $136.1 million, representing 69% year-over-year growth SUNOSI® 3Q 2025 net product revenue of $32.8 million, representing 35% year-over-year growth SYMBRAVO® 3Q 2025 net product sales of $2.1 million sNDA for AXS-05 in Alzheimer’s disease agitation submitted to the FDA Company to host conference call today at 8:00 AM Eastern NEW YORK, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Axsome The ...

$97.8 million in 3Q VYJUVEK revenue and $623.2 million since U.S. launch VYJUVEK launched in Germany in 3Q; launched in France and Japan in 4Q Updated U.S. VYJUVEK label expands eligible patient population and provides greater patient flexibility FDA grants platform technology designation CF interim results expected in 4Q Strong balance sheet, ending the quarter with $864.2 million in cash and investments PITTSBURGH, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) to ...